Theralase Technologies Inc. (FRA:TTX)

Market Cap	40.15M
Revenue (ttm)	612.52K
Net Income (ttm)	-2.66M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,151
Open	0.1080
Previous Close	0.1100
Day's Range	0.1080 - 0.1080
52-Week Range	0.0805 - 0.2160
Beta	n/a
RSI	58.89
Earnings Date	Mar 20, 2026

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle...

• Industry: Electromedical and Electrotherapeutic Apparatus
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TTX

Financial Performance

In 2024, Theralase Technologies's revenue was 1.03 million, a decrease of -3.45% compared to the previous year's 1.07 million. Losses were -4.26 million, -6.89% less than in 2023.

Financial numbers in CAD